This is a preview of subscription content, log in via an institution to check access.
Reference
Skedgel C, et al. Is adjuvant trastuzumab a cost-effective therapy for HER-2/neu-positive T1bN0 breast cancer? Annals of Oncology : 22 Mar 2013. Available from: URL: http://dx.doi.org/10.1093/annonc/mdt069
Rights and permissions
About this article
Cite this article
Adjuvant trastuzumab cost effective in T1bN0 breast cancer?. PharmacoEcon Outcomes News 675, 5 (2013). https://doi.org/10.1007/s40274-013-0277-x
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-013-0277-x